GleanMark

DIRECT BIOLOGICS Trademark

DIRECT BIOLOGICS is a USPTO trademark filed by Direct Biologics, LLC. Status: Pending.

Trademark Facts

MarkDIRECT BIOLOGICS
Serial Number99361536
StatusPending
Filing Date2025-08-27
Mark TypeWord
Nice Classes001 (Chemicals), 005 (Pharmaceuticals), 044 (Medical Services)
OwnerDirect Biologics, LLC
Attorney of RecordAaron D. Hendelman
Prosecution Events11
Latest EventCNSA on 2026-05-08

Goods & Services

Class 001: Exosomes for use in the manufacture of cosmetics and pharmaceuticals; Class 005: Pharmaceutical and therapeutic preparations for the treatment of inflammation, inflammation-derived diseases, acute respiratory disease syndrome (ARDS), Crohn’s disease, perianal fistulizing disease, colitis, pulmonary fibrosis, hair loss, alopecia, psoriasis, ulcers, joint pain, discogenic pain, lumbar and cervical radiculopathy, osteoarthritis, COVID-19, hip labral tears, traumatic brain injury, amyotrophic lateral sclerosis (ALS), chronic regional pain syndrome (CRPS), facial nerve damage, Bell’s Palsey, Ehler’s Danlos Disease, wound care, and skin damage; pharmaceutical and therapeutic preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders; regenerative medicine, namely, pharmaceuticals and therapeutics for the treatment of inflammation, inflammation-derived diseases, acute respiratory disease syndrome (ARDS), Crohn’s disease, perianal fistulizing disease, colitis, pulmonary fibrosis, hair loss, alopecia, psoriasis, ulcers, joint pain, discogenic pain, lumbar and cervical radiculopathy, osteoarthritis, COVID-19, hip labral tears, traumatic brain injury, amyotrophic lateral sclerosis (ALS), chronic regional pain syndrome (CRPS), facial nerve damage, Bell’s Palsey, Ehler’s Danlos Disease, wound care, and skin damage; regenerative medicine, namely, pharmaceuticals and therapeutics for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders; Class 044: Gene therapy; cell therapy; services in the field of regenerative medicine; diagnosing the need for, and administering, regenerative medicine; regenerative medicine services

Recent Prosecution Activity

DateDocumentType
2026-03-23Response to Office ActionROA
2026-01-21Public NotePNR
2026-01-21Non-Final ActionNFIN
2026-01-21XSearch Search SummaryXSS
2025-08-27ApplicationAPP

USPTO Refusals on Record

Related